NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.
Details
- Buyer
- NHS England
- Supplier(s)
35 suppliers
- AVENTIS PHARMA LIMITED
- Accord UK Ltd
- Amgen Ltd
- Astra Zeneca UK Limited
- Bayer Ltd
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Celltrion Healthcare United Kingdom Ltd
- CST Pharma Limited
- Daiichi Sankyo UK Ltd
- Day Lewis Medical Ltd
- Dr Reddy's Laboratories (UK) Ltd
- Eli Lilly and Company Ltd
- Ferring Pharmaceutical
- GEDEON RICHTER (UK) LIMITED
- Gilead Sciences Ltd, 280 High Holborn
- Ipsen
- Janssen Cilag Ltd
- LEO Pharma
- Merck Serono Limited
- MERCK SHARP & DOHME (UK) LIMITED
- Mylan
- Napp Pharmaceuticals Ltd
- Novartis Pharmaceutical UK Ltd
- Novo Nordisk Ltd
- Pfizer Liimted
- Roche Products Ltd
- ROVI BIOTECH LIMITED
- Sandoz
- Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
- Takeda UK Limited
- TECHDOW PHARMA ENGLAND LIMITED
- Teva UK Ltd
- Thornton and Ross
- UCB Pharma Ltd
- UL Global Pharma
- Value
- GBP 56
- Topic
- Pharmaceutical products
- Published
- 23 February 2021
- Source
- uk:find_a_tender
Tender description
CM/PHR/20/5591/01 - Midlands and East, Branded Medicines – Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5591/02 - Midlands and East Branded Medicines – Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 monthsCM/PHR/20/5591/03 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021CM/PHR/20/5591/04 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021 Lot 1: Lot 1: Midlands and East (MAE) Tranche B CM/PHR/20/5591/01 - NHS Framework for the Midlands and East, Branded Medicines – Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2: Midlands and East Cytokine Modulators and other monoclonal antibodies CM/PHR/20/5591/02 - NHS Framework for the Midlands and East Branded Medicines – Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3: (LNW) – Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma CM/PHR/20/5591/03 – NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 4: Lot 4: (SOFE) – Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma CM/PHR/20/5591/04 – NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Timeline
- Completed: Award date25 January 2021
- Completed: Award published23 February 2021Current notice
About the buyer
NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Relevant CPV codes
- 33600000 · Pharmaceutical products
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
6 similar open tenders
See more open tenders related to NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies..
- Open tender
IMP Manufacture, Labelling and Packaging DPS
- Open tender
CPH037 - Enhanced Services (Pharmacies)
- Open tender
Potassium iodide tablets 2024-2026
Related buyers
Buyers similar to NHS England.
- 455£2.1bn
- 367£249.3m
- 353£15.0bn
- 293£2.8bn
- 261£19.7bn
- 252£892.4m
- 243£509.0m
- 203£1.0bn
- 140£895.5m
- 114£59.4m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
